Patent details

Basic Information

Publication number:

EP3033098

PCT Application Number:

US2014051147

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP148359276

PCT Publication Number:

WO2015023894

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

RECOMBINANT FACTOR VIII PROTEINS

French Title of Invention:

PROTÉINES DE FACTEUR VIII DE RECOMBINAISON

German Title of Invention:

REKOMBINANTE FAKTOR-VIII-PROTEINE

SPC Number:

Dates

Filing date:

14/08/2014

Grant date:

22/06/2022

EP Publication Date:

22/06/2016

PCT Publication Date:

19/02/2015

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

22/06/2022

EP B1 Publication Date:

22/06/2022

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

14/08/2022

Expiration date:

14/08/2034

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

15/06/2022

 

 

Name:

Bioverativ Therapeutics Inc.

Address:

225 Second Avenue, Waltham, MA 02451, United States (US)

Inventor

1

Name:

KULMAN, John

Address:

United States (US)

2

Name:

PETERS, Robert T.

Address:

United States (US)

Priority

Priority Number:

201361866017 P

Priority Date:

14/08/2013

Priority Country:

United States (US)

Classification

IPC classification:

A61K 38/36; A61K 38/37; A61K 35/14; C07K 1/00; C07K 14/745; C07K 14/755; C07K 7/08; C07K 14/49; C07K 14/76; C07K 14/705; C07K 14/59; C07K 14/00; A61K 38/00; C07K 14/79; A61P 7/04; A61K 47/60; A61K 47/61; A61K 47/54;

Publication

European Patent Bulletin

Issue number:

202225

Publication date:

22/06/2022

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages